Novo Nordisk Hikes 2026 Outlook Again
Wegovy pill sales jumped 53% from the second quarter, and Novo Nordisk raised its 2026 sales and profit outlook after beating expectations.
- On Wednesday, Novo Nordisk reported third-quarter sales of $11.9 billion, surpassing FactSet estimates as its Wegovy pill beat forecasts.
- The Danish drugmaker is seeking to regain momentum after a tumultuous year in which it fell behind rival Eli Lilly in obesity treatments.
- Wegovy pill sales reached $810 million, up 53% from the second quarter, while adjusted operating profit climbed 27% to 31.72 billion Danish crowns.
- Novo raised its 2026 adjusted sales and operating profit forecast to between +2% and-2%, marking the third guidance increase this year.
- CEO Mike Doustdar said "growth was led by our obesity portfolio, with continued uptake of Wegovy pill in the US," as analysts identify the pill as Novo's primary growth engine.
24 Articles
24 Articles
Fresenius increases sales and increases outlook +++ Growth at Scout24 strongly increases +++ Foreign business strengthens balance sheet of Fraport +++ Continental writes black figures +++ The news blog.
Novo Nordisk reported better-than-expected third-quarter results on Wednesday. The Danish drugmaker's strong performance was driven primarily by strong sales of its tablet-form Wegovy consumer drug, which led the company to raise its full-year profit forecast, CNBC reported.
Reformatorisch Dagblad
The Danish pharmaceutical group Novo has raised its financial outlook for this year, partly due to demand for its weight-loss pill. Demand for Wegovy in the United States is increasing, and the weight-loss pill is also being launched in more and more countries.
Coverage Details
Bias Distribution
- 56% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
